Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market

Mar 26 2012

Related Content

Germany’s Pricing Revolution: Why The World Should Be Watching

Feb 24 2012

Doubling Its Bet In IPF, Gilead Buys Arresto Biosciences For $225 Million

Dec 20 2010

Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle

Feb 14 2012

Germany Issues Benefit Assessment For InterMune’s Esbriet, Despite Orphan Drug Status

Mar 16 2012

$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications

Mar 09 2012

Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis

Feb 11 2011

BMS Bets On Amira's IPF Drug In $325M Acquisition

Jul 22 2011

FDA Meetings With Biosimilar Sponsors Aim To Make 351(k) Pathway OK

Dec 16 2011

InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe

Aug 18 2011

InterMune Likely First To Market In IPF, But Other Firms Poised To Follow

Mar 22 2010

Related Companies

InterMune, Inc.

Bristol Myers Squibb Company

Biogen, Inc.

Gilead Sciences, Inc.

Promedior, Inc.

Stromedix, Inc.

Boehringer Ingelheim GmbH

GSK plc

Epistem Limited

Gilead Sciences, Inc.

Additional Topics

Europe Business Strategies Clinical Trials BioPharmaceutical

More from Europe

More from Geography

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window